The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $46.01

Today's change-0.28 -0.60%
Updated September 30 4:05 PM EDT. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $46.01

Today's change-0.28 -0.60%
Updated September 30 4:05 PM EDT. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd down (U.S.)$0.28

Teva Pharmaceutical Industries Ltd closed lower Friday, dropping (U.S.)$0.28 or 0.60% to (U.S.)$46.01. Over the last five days, shares have lost 10.61% and are down 29.91% for the last year to date. This security has underperformed the S&P 500 by 31.44% during the last year.

Key company metrics

  • Open(U.S.) $46.36
  • Previous close(U.S.) $46.29
  • High(U.S.) $46.76
  • Low(U.S.) $45.76
  • Bid / Ask-- / --
  • YTD % change-29.91%
  • Volume13,279,547
  • Average volume (10-day)6,790,221
  • Average volume (1-month)6,277,490
  • Average volume (3-month)5,818,036
  • 52-week range(U.S.) $45.76 to (U.S.) $66.55
  • Beta0.75
  • Trailing P/E30.72×
  • P/E 1 year forward8.70×
  • Forward PEG1.53×
  • Indicated annual dividend(U.S.) $1.36
  • Dividend yield2.96%
  • Trailing EPS(U.S.) $1.50
Updated September 30 4:05 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.17%

Based on its net profit margin of 8.17%, Teva Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.19%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue5,0384,8104,8814,823
Total other revenue--------
Total revenue5,0384,8104,8814,823
Gross profit2,8772,7912,8472,771
Total cost of revenue2,1612,0192,0342,052
Total operating expense4,6773,6453,9503,813
Selling / general / administrative1,2161,1321,2071,089
Research & development375389446361
Depreciation / amortization4711--7
Interest expense (income), net operating--------
Unusual expense (income)7587192237
Other operating expenses, total120877167
Operating income3611,1659311,010
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax256867861313
Income after tax227639612120
Income tax, total29228249193
Net income254636500103
Total adjustments to net income-66-66-15--
Net income before extra. items254636500103
Minority interest1232-13
Equity in affiliates15-6-114-4
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items188570485103
Inc. avail. to common incl. extra. items188570485103
Diluted net income188570485103
Dilution adjustment0000
Diluted weighted average shares920920876862
Diluted EPS excluding extraordinary itemsvalue per share0.200.620.550.12
Dividends per sharevalue per share0.000.340.340.34
Diluted normalized EPSvalue per share0.930.630.710.30